          |
 |
2016 Agenda and Abstracts | < Previous | Next > 2016 OMIG Abstract 11 Sustained Release of Moxifloxacin by Intracameral Cross-linked Collagen Droplets Purpose: While intracameral antibiotic injections have been advocated as prophylaxis against endophthalmitis, they are quickly diluted by fresh aqueous humor as well as lost via outflow through the trabecular meshwork. We have devised a unique method to cross-link collagen that traps antibiotic within a “molecular cage”. This provides a biodegradable slow release delivery system that continuously delivers moxifloxacin at bacteriocidal levels for 72 hours. Method: Derivatized human collagen was cross-linked by a novel process and 1 mg of moxifloxacin is added. This immediately forms a small viscoelastic droplet which contains the antibiotic. The mixture is placed in normal saline and aliquots were withdrawn at 24, 48 and 72 hours. Moxifloxacin levels were measured by HPLC at each time point. To replicate the fluid dynamics of the anterior chamber, a 250 ul vial was fitted with an entrance and exit port. The collagen/antibiotic droplet was placed in the artificial anterior chamber and normal saline was infused at 2.5 ul/min via a pump. The outflow was collected at the same time points and the levels of moxifloxacin were analyzed by HPLC. Results: The cross-linked collagen mixture slowly hydrolyzed releasing the antibiotic. In the static model, at all time points, moxifloxacin was 10-20 times higher than the bacteriocidal levels needed for pathogens. In the dynamic model, there was 45% less antibiotic in the outflow but still well above the MIC for most pathogens at all time points. Upon contact with fluid, there was an initial burst of antibiotic released in the first 5 minutes and then there was a consistent release of antibiotic above therapeutic levels. Conclusion: The use of cross-linked collagen can provide a sustained release of medication in the anterior chamber. This method can eliminate the need for patients to self administer post operative antibiotic eye drops. P 2016
Agenda and Abstracts | < Previous | Next >
|
|
